BCPC on Nasdaq
BALCHEM CORP
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Ingevity Corp, Ecovyst Inc. or Perimeter Solutions, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
35.7%Gross margin3
20.2%Operating margin3
14.9%Net margin3
8.8%Revenue growth, 20253
12.3%Return on equity3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product Sales brought in 100% of the revenue BALCHEM CORP broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Product Sales | $920.0M | $951.9M | $1.0B |
| Royalty | $2.5M | $1.7M | $1.9M |
Business segments
Human Nutrition and Health brought in 64% of the revenue BALCHEM CORP broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Human Nutrition and Health | $550.8M | $600.3M | $659.4M |
| Animal Nutrition and Health | $238.3M | $214.7M | $230.9M |
| Specialty Products | $126.0M | $132.7M | $141.0M |
Regions
United States brought in 73% of the revenue BALCHEM CORP broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $689.6M | $723.3M | $759.4M |
| Outside the United States | $232.8M | $230.4M | $277.7M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue64¢$666.5M
- Research and development2¢$18.5M
- Other costs15¢$153.1M
- Income tax4¢$44.2M
- Profit15¢$154.8M
Out of $1.0B in revenue.3
Where each dollar of operating cash went, fiscal 2025
- Dividends paid13¢$28.3M
- Share buybacks50¢$107.6M
- Kept or used elsewhere37¢$80.6M
Out of $216.6M of cash from operations.3
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net sales | $1.0B | $953.7M | $922.4M |
| Cost of sales | $666.5M | $617.5M | $620.4M |
| Gross margin | $370.6M | $336.2M | $302.1M |
| Selling expenses | $75.4M | $68.9M | $74.4M |
| Research and development expenses | $18.5M | $16.8M | $15.0M |
| General and administrative expenses | $67.4M | $67.6M | $53.4M |
| Total operating expenses | $161.3M | $153.3M | $142.9M |
| Earnings from operations | $209.3M | $182.9M | $159.2M |
| Interest expense, net | $10.2M | $16.5M | $22.6M |
| Other expense (income), net | $77.0K | -$72.0K | -$681.0K |
| Total other expenses | $10.3M | $16.5M | $21.9M |
| Earnings before income tax expense | $199.0M | $166.5M | $137.3M |
| Income tax expense | $44.2M | $38.0M | $28.7M |
| Net earnings | $154.8M | $128.5M | $108.5M |
| Net earnings per share - basic (in dollars per share) | $4.80 | $3.97 | $3.38 |
| Diluted net earnings per common share (in dollars per share) | $4.75 | $3.93 | $3.35 |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $74.6M | $49.5M | |
| Accounts receivable, net of allowance for credit losses of $862 and $909 at December 31, 2025 and 2024, respectively | $143.6M | $119.7M | $125.3M |
| Inventories, net | $131.4M | $130.8M | |
| Prepaid expenses | $9.8M | $8.1M | |
| Other current assets | $6.2M | $5.7M | |
| Total current assets | $365.6M | $313.8M | |
| Property, plant and equipment, net | $306.6M | $282.2M | |
| Goodwill | $816.4M | $780.0M | $778.9M |
| Customer relationships and lists | $133.0M | $132.5M | |
| Other intangible assets with finite lives, net | $30.3M | $32.6M | |
| Right of use assets - operating leases | $14.7M | $15.3M | |
| Right of use assets - finance lease | $1.5M | $1.7M | |
| Other non-current assets | $18.1M | $17.3M | |
| Total assets | $1.7B | $1.6B | |
| Trade accounts payable | $60.4M | $54.7M | |
| Accrued expenses | $49.3M | $43.8M | |
| Accrued compensation and other benefits | $27.9M | $22.9M | |
| Dividends payable | $31.0M | $28.5M | $25.7M |
| Income tax payable | $3.9M | $4.5M | |
| Operating lease liabilities - current | $3.6M | $3.1M | |
| Finance lease liabilities - current | $205.0K | $194.0K | |
| Total current liabilities | $176.4M | $157.7M | |
| Revolving loan | $164.0M | $190.0M | |
| Deferred income taxes | $54.1M | $43.7M | |
| Operating lease liabilities - non-current | $11.3M | $13.0M | |
| Finance lease liabilities - non-current | $1.5M | $1.7M | |
| Other long-term obligations | $21.4M | $19.3M | |
| Total liabilities | $428.8M | $425.5M | |
| Preferred stock, $25 par value. Authorized 2,000,000 shares; none issued and outstanding | $0 | $0 | |
| Common stock, $.0667 par value. Authorized 120,000,000 shares; 32,058,121 shares issued and outstanding at December 31, 2025 and 32,527,244 shares issued and outstanding at December 31, 2024, respectively | $2.1M | $2.2M | |
| Additional paid-in capital | $92.3M | $174.0M | |
| Retained earnings | $1.1B | $997.5M | |
| Accumulated other comprehensive income (loss) | $41.5M | -$23.7M | |
| Total stockholders equity | $1.3B | $1.1B | $1.1B |
| Total liabilities and stockholders equity | $1.7B | $1.6B | |
| Accounts receivable, allowance for doubtful accounts | $862.0K | $909.0K | |
| Preferred stock, par value (in dollars per share) | $25.00 | $25.00 | |
| Preferred stock, shares authorized (in shares) | 2.0M shares | 2.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.07 | $0.07 | |
| Common stock, shares authorized (in shares) | 120.0M shares | 120.0M shares | |
| Common stock, shares issued (in shares) | 32.1M shares | 32.5M shares | |
| Common stock, shares outstanding (in shares) | 32.1M shares | 32.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net earnings | $154.8M | $128.5M | $108.5M |
| Depreciation and amortization | $45.7M | $48.0M | $54.9M |
| Stock compensation expense | $18.1M | $16.7M | $16.1M |
| Deferred income taxes | $6.3M | -$6.8M | -$10.8M |
| (Recovery of) provision for credit losses | -$97.0K | $299.0K | $37.0K |
| Unrealized gain on foreign currency transactions and deferred compensation | -$680.0K | -$100.0K | -$733.0K |
| Asset impairment charge and (gain) loss on disposal of assets | -$58.0K | $1.7M | $7.0M |
| Change in fair value of contingent consideration liability | $0 | -$91.0K | -$11.3M |
| Accounts receivable | -$20.9M | $5.6M | $7.0M |
| Inventories | $3.6M | -$22.8M | $10.5M |
| Prepaid expenses and other current assets | -$1.3M | $225.0K | -$3.5M |
| Accounts payable and accrued expenses | $11.3M | $9.1M | $3.6M |
| Income taxes | -$1.1M | -$583.0K | $2.2M |
| Other | $865.0K | $2.4M | $305.0K |
| Net cash provided by operating activities | $216.6M | $182.0M | $183.8M |
| Capital expenditures and intangible assets acquired | -$43.5M | -$35.7M | -$37.9M |
| Cash paid for acquisitions, net of cash acquired | -$323.0K | -$24.2M | -$1.3M |
| Proceeds from sale of assets | $274.0K | $359.0K | $1.9M |
| Proceeds from settlement of net investment hedge | $0 | $0 | $2.7M |
| Investment in affiliates | -$353.0K | -$270.0K | -$290.0K |
| Net cash used in investing activities | -$43.9M | -$59.7M | -$34.8M |
| Proceeds from revolving loan | $88.0M | $26.0M | $18.0M |
| Principal payments on revolving debt | -$114.0M | -$145.6M | -$149.0M |
| Principal payments on finance lease | -$194.0K | -$216.0K | -$222.0K |
| Proceeds from stock options exercised | $9.3M | $17.2M | $5.2M |
| Dividends paid | -$28.3M | -$25.6M | -$22.9M |
| Repurchases of common stock | -$107.6M | -$5.7M | -$4.5M |
| Net cash used in financing activities | -$152.8M | -$133.8M | -$153.3M |
| Effect of exchange rate changes on cash | $5.2M | -$3.4M | $2.3M |
| Increase (decrease) in cash and cash equivalents | $25.1M | -$14.9M | -$2.1M |
Recent filings
- Sep 24, 20263
- Jul 31, 20268-K
- Jul 31, 202610-Q
- Jul 27, 20268-K
- Jun 22, 20268-K
- Jun 18, 202611-K
- Apr 30, 20268-K
- Apr 30, 202610-Q
- Apr 29, 2026SCHEDULE 13G
- Apr 28, 2026SCHEDULE 13G
- Apr 27, 2026DEF 14A
- Apr 27, 2026DEFA14A
- Apr 7, 20263
- Mar 26, 2026SCHEDULE 13G/A
- Feb 20, 20268-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARBALCHEM CORP filings on SEC EDGAR
- 2SEC EDGARBALCHEM CORP filings on SEC EDGAR
- 3SEC EDGARBALCHEM CORP 10-K for fiscal 2025
- 4SEC EDGARBALCHEM CORP 10-K for fiscal 2019
- 5SEC EDGARBALCHEM CORP 10-K for fiscal 2020
- 6SEC EDGARBALCHEM CORP 10-K for fiscal 2021
- 7SEC EDGARBALCHEM CORP 10-K for fiscal 2022
- 8SEC EDGARBALCHEM CORP 10-Q for fiscal 2026
- 9SEC EDGARBALCHEM CORP 10-Q for fiscal 2026
- 10SEC EDGARBALCHEM CORP 10-K for fiscal 2019